Loading patent…
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Genome Research Limited, Dana-Farber Cancer Institute, Inc.
InventorsWilliam Curtis Reinhold, Mathew Garnett, Vinodh Nalin Rajapakse, Yves Pommier, Augustin Luna
Estimating the term…
The disclosure provides a method of treating triple negative breast cancer in a patient, comprising administering a therapeutically effective amount of a compound selected from oxyphenisatin, oxyphenisatin acetate, and bisacodyl, or the pharmaceutically acceptable salts or hydrates of any of the foregoing to the patient. The disclosure also provides methods of using oxyphenisatin or bisacodyl, or a salt or hydrate thereof, as a first active agent in combination with one or more additional active agents to treat triple negative breast cancer. The disclosure further provides methods for determining whether a patient suffering from triple negative breast cancer would be responsive to treatment with oxyphenisatin or bisacodyl.
A method of treating triple negative breast cancer in a patient, comprising administering a therapeutically effective amount of a compound selected from bisacodyl and pharmaceutically acceptable salts and hydrates thereof to the patient.
A method of treating a patient having triple negative breast cancer, the method comprising
A method of treating triple negative breast cancer in a patient, comprising administering a therapeutically effective amount of a compound selected from bisacodyl and pharmaceutically acceptable salts and hydrates thereof to the patient, wherein the patient has a tumor that has elevated expression of SCL31A1, ABCA12, SPIB, or PIK3R1.
Dependencies are inferred from the claim text.